Drug makers are scrambling to produce the next wave of obesity drugs. Just one problem. The payers expected to pay are pushing back. For years, the obesity drug conversation has focused on clinical efficacy: How much weight loss can the next drug achieve? 20%, 25%? Perhaps even more. But that may be the wrong question. Instead, manufacturers face this question: Can you demonstrate enough incremental clinical and economic value to justify paying for chronic treatment for millions of patients? Employers and insurers are asking it, and the data suggests the bar is being raised dramatically.
Employers Are Discovering the GLP-1 Math
GLP-1 drugs pose a unique challenge for benefit managers. They can work brilliantly for individual patients but pose a huge budget impact at the population level.
According to Business Group on Health’s September 2026 update, 67% of large employers surveyed already cover GLP-1 drugs for weight management. However, only 72% of those employers are likely to provide coverage in 2027. And among employers that cover GLP-1s, nearly 80% report the drugs are driving up health costs.
Mercer has reported similar findings. Total annual employer health-benefit costs will rise by 6.7% in 2026 to exceed $18,500 per employee. Prescription drug costs are rising even faster, at about 9%. According to Mercer, 6% of large employers are dropping coverage of weight-loss drugs from their GLP-1 formularies in 2026.
Another 5% plan to drop coverage in 2027 or are considering doing so. Twenty-seven percent have restricted or plan to restrict utilization management. One 2026 survey found GLP-1 weight-loss drugs accounted for nearly 11.4% of annual drug claims among employers that offer coverage. That’s a huge amount of spending devoted to a single category of drugs.
The obesity marketplace doesn’t suffer from a demand issue. It has an affordability issue.
The Industry May Be Optimizing for the Wrong Endpoint
The obesity pipeline is massive. Consulting firm Mercer calculates that there are currently almost 150 obesity drugs in the development pipeline, many of which work through mechanisms other than GLP-1.
Competition in the scientific arena is fierce and is producing remarkable outcomes. Lilly’s retatrutide, an investigational product that activates GIP, GLP-1 and glucagon receptors, is one example. In late-stage trial results announced last week, patients suffering from obesity or overweight and type 2 diabetes lost up to 20.8% of their body weight at week 80.
In patients with severe obesity and existing cardiovascular disease, retatrutide produced weight losses of up to 22.6%. Lilly expects to file for U. S. approval the drug in early 2027. Novo Nordisk’s CagriSema produced ~23% weight loss in a recent Phase 3 head-to-head trial, though it did not meet non-inferiority to tirzepatide. Amgen is taking a novel approach with its drug candidate MariTide, which is in Phase 3 development and has the potential to allow monthly, or perhaps even less frequent, maintenance dosing rather than weekly administrations. Science-wise, these are astounding achievements.
A rep from the pharma company walks into your office and says: “Our new drug delivers 23% weight loss versus 20%.” You might say: “That’s wonderful. But how is that going to impact my pharmacy budget?” Dialogue like that could dictate which drugs in the pipeline become commercial winners.
The First Disruption Has Already Arrived: Price Competition
Something big happened in 2026 that could matter more than yet another slight edge in weight loss. Lilly gained FDA approval of its oral GLP-1, Foundayo (orforglipron), back in April. Lilly introduced Foundayo with self-pay prices starting at $149/month. Eligible patients with commercial insurance can pay as little as $25/month. Novo Nordisk also advertises direct-pay Wegovy prices starting in the hundreds instead of the $1,000++ world we’re used to. Suddenly, the competitive landscape changes. Future obesity drugs won’t just compete against Wegovy and Zepbound based on weight loss. They’ll have to compete against heavily discounted GLP-1 medications. Price per pound lost may matter more than absolute weight loss going forward.
The Future Isn’t “No Coverage.” It’s Selective Coverage.
I don’t think employer resistance signals the end of the obesity-drug boom. I think it signals the beginning of the obesity drug market’s maturity. The first phase of the GLP-1 revolution was basically: Does it work? Answer: Yes.
The second phase was: How many people want this? Answer: Millions. We’re now entering the third phase: Who should get it, for how long, at what price and contingent on what measurable results? That’s a very different conversation. And it produces a very different market. Case in point: Employers are moving toward stricter eligibility requirements.
Among employers that provide GLP-1 coverage, 90% have minimum BMI requirements, 54% require obesity plus another chronic condition and 29% require participation in lifestyle-modification programs. Here’s the kicker: a 2026 benefits survey revealed that 90% of respondents were moderately or very concerned about GLP-1 affordability. At the same time, 72% said discontinuation rates factor into their coverage decisions.
Therefore, future obesity drugs will probably need to win in at least one of five ways:
- Lower price. A drug delivering somewhat less weight loss for dramatically less money could be extremely attractive to employers.
- Superior outcomes. Twenty-five percent weight loss matters, but reductions in cardiovascular events, sleep apnea, kidney disease, diabetes progression, or hospitalizations may matter considerably more to payers.
- Better persistence. A medication patients actually remain on—and one that can transition to inexpensive maintenance therapy—could have major economic advantages.
- Greater convenience. Oral medications and monthly or quarterly maintenance dosing could substantially change adherence and treatment costs.
- Targeted treatment. Instead of treating obesity as one enormous population, payers may increasingly identify patients with obesity plus cardiovascular disease, diabetes, sleep apnea or other high-cost conditions where the economic case for treatment is strongest.
The Biggest Opportunity May Be Maintenance
Few commentaries discuss what happens once obesity patients lose weight. Are they expected to stay on expensive branded drugs for life? If so, employers could be on the hook for permanent pharmacy liabilities.
Real-world evidence cited by Mercer shows that only one in 12 members are still on GLP-1 drugs three years after starting them, though persistence is getting better. Either way, that leaves a huge trough left behind. The real blockbuster drug over the next decade may not be the medication that gets someone from 250 pounds down to 190. It may be the therapy that allows them to STAY at 190 pounds cost-effectively. Think about a treatment paradigm in which patients receive robust induction therapy for one year to 18 months, then transition into a low-cost oral medication, low-dose drug or monthly/quarterly injection. Such regimens could drastically change the economic profile. Amgen’s current portfolio is interesting because of the prolonged maintenance schedules it is evaluating – every eight weeks or quarter dosing. That could be more important to employers than an additional two percentage points of weight loss.
Obesity Drugs Will Have to Become Cardiometabolic Drugs
There’s another big trend afoot. The blockbuster drugs may no longer be marketed principally as “weight-loss drugs.” Instead, drug makers will strive to show that their drugs prevent costly diseases and medical episodes. Examples of this approach are already here.
Drug development programs routinely assess cardiovascular disease, obstructive sleep apnea, heart failure, kidney outcomes, and metabolic liver disease. That’s not just expansion of indications. It’s financial engineering. A “$5,000/year obesity drug” looks pricey when compared to pounds lost. But the same drug looks much more appealing if a manufacturer can prove that it reduces heart attacks, strokes, hospitalizations, dialysis, sleep apnea machines, or diabetes. So the future reimbursement pitch won’t be: “Our drug causes 24% weight loss.” Instead it will be: “Give this drug to these 1,000 high-risk workers and here are the medical events–and dollar savings–we think you can prevent.” That’s a lot more compelling discussion with a CFO.
The Market Could Eventually Split in Two
We may well wind up with something akin to the cholesterol marketplace. On one side, you’ll have cheap therapies accessible to millions of patients. On the other, you’ll have premium drugs that are tightly managed and restricted to patients with extreme obesity or high cardiometabolic risk. In the middle, you’ll have vigorous formulary management.
Drugmakers can no longer presume that every next-gen obesity medication entering Phase 3 development is destined to become a blockbuster. Far from it. Clinical success may be far more attainable than commercial success.
Medications that produce impressive weight loss but come with a $12,000 annual price tag may find themselves struggling to compete with drugs that produce marginally less weight loss for $2,000-$4,000 per year. Employers have already shown us where their priorities stand.
According to the International Foundation of Employee Benefit Plans, only 36% of employers surveyed cover GLP-1s for diabetes and weight loss, while 60% cover GLP-1s for diabetes management alone. That’s a significant distinction. Employers aren’t turning their back on GLP-1 science; they’re rationing patient access based on perceived medical need and economic value.
Pharma’s Coming GLP-1 Reality Check
Implicit in many obesity-market predictions is this thought: Obstructive market realities aside, because obesity medicine serves such a large swath of the population, the market for obesity drugs must be correspondingly large. It’s not quite that simple.
A target population in the tens of millions means very little if your healthcare system can’t pay for treatment of more than a tiny fraction of those millions at branded-drug prices. Consequently, the companies that win during the next round of obesity medicine will not necessarily be the ones with the biggest molecules or the most potent biological activity. What matters now is which companies can crack the four-variable obesity equation: efficacy + persistence + outcomes + affordability. That’s also why employer resistance may prove positive for the obesity drug market in the long run. It will push drug companies to compete on a factor they haven’t really had to focus on during obesity medicine’s first GLP-1 gold rush: value. Obesity drug developers proved during round one that pharmacologic treatment can work. Now they have to prove we can afford it.
There Are Options, However
If one GLP-1 drugmaker launched an effective obesity medicine that cost just $150–$250/month instead of $1,000+/month, that would reset the market. Suddenly, employers and insurers limiting access strictly because of cost could point to access economics as justification for broader access. GLP-1 treatment for obesity would shift from a highly-managed specialty benefit to a blockbuster chronic therapy marketed to the masses.
A cheaper competitor would also create pricing pressure on Lilly, Novo Nordisk and other incumbents to raise rebates or lower their net prices, and give pharmacy benefit managers (PBMs) a quick reason to favor that drug on their formularies.
Most of all, cheap competition could turn those modest differences in weight-loss effectiveness on their head: An employer might well prefer a $2,400/year drug that leads to 15–18% weight loss over a $10,000/year drug that leads to 20–23% weight loss. In that case, the billion-dollar winner in the obesity drug market might not be the one that develops the most effective drug—it might be the first developer of a GLP-1 drug that’s good enough for the healthcare system to prescribe to millions of patients.
